Today’s global market has multiple standards. Patients in low- and middle-income countries often receive poor-quality medicines. Despite increasing awareness about the issue and the launch of some initiatives, the divide in quality of pharmaceuticals between

Multidrug-resistant tuberculosis (MDR-TB) is a major threat to global TB control. MDR-TB treatment regimens typically have a high pill burden, last 20 months or more and often lead to unsatisfactory outcomes. A 9–11 month regimen

Collaborative clinical research that addresses the health needs of low and middle-income countries (LMICs) has become more frequent recently. Such research includes therapeutic and diagnostic trials for neglected tropical diseases (NTDs), and is often conducted

Trauma is one of the leading causes of death in developing countries – where there is limited access to good quality emergency care. Doctors Without Borders/Médecins Sans Frontières (MSF) delivered a standard package of care

The Doctors Without Borders/Médecins Sans Frontières (MSF) ethics review board (ERB) was solicited in an unprecedented way to provide advice and review research protocols in an ‘emergency’ mode during the recent Ebola epidemic. Twenty-seven Ebola-related

Multidrug-resistant tuberculosis (MDR TB), is a significant threat to TB control efforts. Previous prevailing views that resistance was mainly acquired through poor treatment led to decades of focus on drug-sensitive rather than drug-resistant (DR) TB.

This study assesses the feasibility and added value of using the Xpert Ebola Assay in an Ebola control program in Guinea. Several logistic and safety issues were identified and the study suggests that implementation of

A recent editorial in Lancet, advocates for a better and more universal access to healthcare for refugees landing in Europe. The arguments of equity, social justice and cost– effectiveness are clearly explained in the comment.

Leprosy remains an important cause of preventable disabilities. After the advent of multidrug therapy, new leprosy cases have come down dramatically. Despite this achievement, India, which contributes 60% to the global leprosy burden, faces some

Shortages of vaccines for epidemic diseases, such as cholera, meningitis, and yellow fever, have become common over the past decade, hampering efforts to control outbreaks through mass reactive vaccination campaigns. Additionally, various epidemiological, political, and